|
End-of-day quote
Taipei Exchange
13/08/2026
|
5-day change | 1st Jan Change | ||
| 22.80 TWD | -0.22% |
|
-1.94% | -11.46% |
| 08-03 | GlycoNex Inc Doses First Patient In Phase I Trial Of GNX1021 | CI |
| 06-11 | Glyconex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar Spd8 | CI |
Main competitors
| Change | 5-day change | 1-month change | 3-month change | YTD change | 1-year change | 3-year change | 5-year change | 10-year change | Capi.($) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
 | -0.22% | -1.94% | -7.69% | +0.44% | -11.46% | -0.87% | -21.38% | -17.54% | -45.06% | 79.87M | |
| -1.41% | -1.61% | -3.33% | +19.94% | +4.69% | +2.07% | +13.92% | -22.47% | +197.88% | 49.24B | |
| -1.59% | +2.12% | +9.81% | +34.72% | +153.61% | +460.02% | +573.56% | +690.30% | - | 43.3B | |
| -0.85% | +7.95% | +17.12% | +12.47% | +17.18% | +15.77% | +80.09% | +28.90% | +1,164.69% | 40.48B | |
| -0.08% | +3.91% | +16.37% | +40.11% | +7.15% | +26.96% | +9.86% | -2.67% | +216.13% | 39.75B | |
| 0.00% | +3.59% | +15.36% | +11.34% | +17.18% | +20.51% | +48.00% | -10.82% | +154.39% | 32.67B | |
| -3.61% | -1.45% | -7.16% | +1.09% | - | - | - | - | - | 16.23B | |
| -2.52% | -0.52% | +9.76% | +37.33% | +3.61% | +24.35% | +118.05% | +227.51% | +1,975.43% | 16.24B | |
| +0.51% | +0.95% | +2.12% | +18.62% | +12.92% | +4.35% | +22.20% | -38.99% | +86.25% | 14.04B | |
| -1.09% | +5.94% | +22.42% | +72.72% | +41.00% | +81.46% | +31.15% | -31.60% | +239.21% | 13.43B | |
| +0.19% | +3.92% | +0.83% | +42.68% | -8.09% | -5.00% | -35.18% | -29.94% | +118.67% | 12.92B | |
| +3.97% | +25.76% | +46.13% | +82.35% | +75.17% | +61.48% | +68.81% | -45.87% | - | 12.3B | |
| -0.08% | +0.38% | +1.14% | +60.77% | +22.72% | +31.91% | -14.48% | -38.18% | +160.33% | 11.25B | |
| -1.03% | -7.54% | -11.12% | +1.93% | -12.38% | +78.81% | +514.80% | +301.90% | +2,405.94% | 10.6B | |
| -4.63% | -0.46% | +17.14% | +6.23% | +25.01% | +651.19% | +2,133.09% | +78.00% | - | 10.29B | |
| -0.07% | -0.03% | +0.47% | +60.17% | +78.13% | +259.88% | +520.44% | - | - | 10.14B | |
| -0.59% | +17.71% | -2.93% | +18.28% | -8.06% | -22.03% | - | - | - | 9.8B | |
| -0.39% | +3.58% | +16.58% | +45.76% | +73.37% | +166.96% | +700.74% | +217.51% | +1,208.73% | 9.8B | |
| +0.34% | +7.53% | +3.64% | +33.68% | +47.05% | +180.92% | +470.67% | +112.12% | - | 9.51B | |
| -1.17% | +2.53% | -1.55% | -28.00% | -29.38% | +29.63% | +38.91% | +40.80% | +59.49% | 9.28B | |
| Average | -0.72% | +3.08% | +7.25% | +28.63% | +26.81% | +108.86% | +292.96% | +85.82% | +610.93% | 18.57B | |
| Weighted average by Cap. | -0.83% | +3.13% | +8.85% | +28.13% | +33.85% | +108.66% | +225.82% | +114.61% | +570.74% |
- Stock Market
- Stocks
- 4168 Stock
- Sector GlycoNex Incorporation
Select your edition
All financial news and data tailored to specific country editions
